55results about How to "Protect heart function" patented technology

The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use for treating heart failure, in particular heart failure following myocardial infarction.

The invention discloses a function and application of ubiquitin specific protease 4 (USP4) in treating cardiac hypertrophy, and belongs to the field of gene functions and application. The mutual relation between the expression of the USP4 and cardiac hypertrophy is determined; research results show that in a cardiac hypertrophy occurrence model, the expression of the USP4 is significantly reduced compared with a normal group; by restraining the expression of the USP4, the cardiac hypertrophy and fibrosis are significantly promoted, and the cardiac function is deteriorated; by promoting the expression of the USP4, cardiac hypertrophy and fibrosis are significantly restrained, and the cardiac function is protected. Accordingly, the USP4 can be used as a target gene for screening and preparing the medicine which protects the cardiac function, resists cardiac fibrosis and / or prevents, relieves and / or treats cardiac hypertrophy, and an effective new way is provided for treating cardiac hypertrophy.

The invention discloses a function and an application of TRIM32 (Tripartite motif 32) in treating myocardial hypertrophy and belongs to the field of gene functions and applications. The mutual relation between expression of TRIM32 and myocardial hypertrophy is determined, a research result proves that in a model where myocardial hypertrophy occurs, the expression of TRIM 32 is remarkably reduced than that of a normal group; if expression of TRIM 32 is inhibited, activation of an AKT signal path is remarkably promoted, myocardial hypertrophy and fibrosis are promoted, and the cardiac function is deteriorated; if overexpression of TRIM 32 is promoted, activation of the AKT signal path is remarkably inhibited, myocardial hypertrophy and fibrosis are inhibited, and the cardiac function is protected. Therefore, TRIM32 can be taken as a target gene and used for screening or preparing a drug for protecting the cardiac function, preventing cardiac fibrosis and / or preventing, relieving and / or treating myocardial hypertrophy, and a new effective way is provided for treatment of myocardial hypertrophy.

The invention relates to a fixing device for a left ventricular aneurysm and a system of the device. The fixing device comprises a skeleton and a film; the skeleton is generally in a rib shape and comprises fix nickel-titanium alloy wires and one steel cap; one end of each nickel-titanium alloy wire is sleeved with the steel cap for fixation, and the other end of each nickel-titanium alloy wire isinclined outward at 30 degrees to form a tip end; the film is generally in an umbrella surface shape and is sewed on the skeleton to cover the skeleton. Compared with current treatment methods, a method involved in the fixing device has the advantages that a wound is small and recovers quickly; since the ventricular aneurysm is fixed, the increased left ventricular size is reduced, and heart functions are directly protected and improved; the bulged ventricular aneurysm is fixed through a minimally invasive combined intervention method, the ventricular aneurysm does not bulge during ventricular systole, the left ventricular size is reduced but is not lower than a normal value, the left ventricular output amount is decreased, and a cardiac ejection function is improved.

The invention discloses a function and application of activin receptor-like kinase7 (ALK7) in treatment of a cardiac hypertrophy disease. According to the invention, the relationship between an ALK7 gene and the cardiac hypertrophy is determined: when the cardiac hypertrophy occurs, the expression of ALK7 is obviously reduced; the interference of ALK7 and over-expressed adenovirus are respectively used for promoting and inhibiting cardiomyocyte hypertrophy; ALK7 gene knockout has the effect of remarkably enhancing the activation of MEK1 / 2 / ERK1 / 2 and Smad2 / Samd3 signal channels so that the cardiac hypertrophy and fibrosis are promoted and the heart function is worsened; over-expression of the ALK7 gene has the effect of remarkably reducing the activation of MEK1 / 2 / ERK1 / 2 and Smad2 / Samd3 signal channels so that the cardiac hypertrophy and fibrosis are inhibited and the heart function is improved. Therefore, the ALK7 gene can be used as a target gene in gene therapy and can be used for preparing a medicine for protecting the heart function and / or preventing, relieving and / or treating the cardiac hypertrophy, thus providing a new way for treating the cardiac hypertrophy.

The invention discloses functions and application of growth arrest-specific proteins 6 (GAS6) to treating myocardial hypertrophy, and belongs to the field of functions and application of genes. The functions and the application have the advantages that relationships between expression of the GAS6 and the myocardial hypertrophy are determined, and as shown by research results, expression of the GAS6 in models with the myocardial hypertrophy is obviously improved as compared with normal groups; myocardial hypertrophy and fibrosis can be obviously inhibited by means of inhibiting expression of the GAS6, and cardiac functions can be protected; the myocardial hypertrophy and fibrosis can be obviously promoted if over-expression of the GAS6 is promoted, and the cardiac functions can be deteriorated; the GAS6 can be used as a medicine target and can be used for screening medicine for protecting the cardiac functions, resisting the cardiac fibrosis and / or preventing, relieving and / or treating the myocardial hypertrophy; inhibitors of the GAS6 can be used for preparing medicine for protecting the cardiac functions, resisting the myocardial hypertrophy and / or preventing, relieving and / or treating the myocardial hypertrophy, and an effective novel way can be provided for treating the myocardial hypertrophy.

The invention discloses a function and an application of an inhibitor SIKE of IkB kinase epsilon in cardiac hypertrophy, belonging to the field of functions and applications of genes. According to the function and application of the IkB kinase epsilon inhibitor (SIKE) in treating cardiac hypertrophy, an interrelation between the expression of SIKE and cardiac hypertrophy is determined; by adopting cardiac specific SIKE transgenic mice and non-GMOs (genetically modified organisms) as experimental objects, a cardiac hypertrophy disease model is simulated by virtue of a transverse aortic constriction operation; and a result shows that the SIKE gene over-expression can be used for significantly inhibiting cardiac hypertrophy and fibrosis of cardiac hypertrophy, and can be used for improving cardiac functions. Therefore, an SIKE gene can serve as a medicament target for screening medicaments which are used for protecting heart functions, and / or preventing, relieving and / or treating cardiac hypertrophy; the SIKE gene can be used as a target gene in gene therapy, can be used for designing and preparing the medicaments and / or biological reagents which are used for protecting the heart functions, and / or preventing, relieving and / or treating cardiac hypertrophy, and can provide an effective new route for treating cardiac hypertrophy.

The invention discloses a function and application of a dual-specificity phosphatase 14 (DUSP 14) in curing cardiac hypertrophy, belonging to the field of gene function and application. The mutual relation between the expression of the DUSP 14 and cardiac hypertrophy is determined, and research results show that in a model with cardiac hypertrophy, compared with a normal group, the expression of the DUSP 14 is remarkably reduced; inhibiting the expression of the DUSP 14 remarkably promotes cardiac hypertrophy and fibrosis and deteriorates a cardiac function, and promoting the overexpression of the DUSP 14 remarkably inhibits cardiac hypertrophy and fibrosis and protects the cardiac function. Therefore, the DUSP 14 can serve as a target gene for screening drugs capable of protecting the cardiac function, resisting cardiac fibrosis and / or preventing, relieving or curing cardiac hypertrophy, and for preparing the drugs capable of protecting the cardiac function, resisting cardiac hypertrophy and / or preventing, relieving or curing cardiac hypertrophy, thus providing an effective new approach for the curing of cardiac hypertrophy.

The invention discloses a function and application of Carabin for treating cardiac hypertrophy, belonging to the field of functions and applications of genes. By virtue of the function and application of Carabin for treating cardiac hypertrophy, cardiac specific Carabin transgenic mice and non-genetically modified organisms are used as experiment targets; a relation between the expression of Carabin gene and the cardiac hypertrophy is researched by simulating a cardiac hypertrophy disease model by virtue of an aortic arch narrow operation; results show that the cardiac hypertrophy and fibrosis can be remarkably suppressed by over expression of the Carabin gene, and the heart function can be improved, namely that the Carabin gene has the functions of protecting the heart function and suppressing the cardiac hypertrophy. By virtue of the function of the Carabin gene, Carabin can be used for preparing medicines for protecting the heart function and / or preventing, relieving and / or treating the cardiac hypertrophy, so that an effective novel way is provided for the treatment of the cardiac hypertrophy.

The invention belongs to the technical field of health care product, and especially relates to a traditional Chinese medicine composition capable of relieving autonomic nervous dysfunction, and a preparation method and a product thereof. The traditional Chinese medicine composition is composed of, by weight, 10 to 100 parts of poria cocos and 10 to 100 parts of spine date seed. It is confirmed byexperiments that the traditional Chinese medicine composition is capable of improving depression anxiety symptoms effectively, protecting autonomic nerve and cardiac functions, improving neuronal celldamages, and relieving autonomic nervous dysfunctions such as anxiety, depression, attention-deficit disorders, impaired study and memory capacity, and functional gastrointestinal disorders caused bylong term pressure or endocrine dyscrasia; the effect is better than that of independent using of poria cocos or spine date seed. The raw materials which can be taken as both food and medicine are adopted, simplification and optimization of ancient prescription < wild jujube seed decoction> is realized, the application range of Chinese herbal medicines in improvement of autonomic nervous dysfunctions is widened, the traditional Chinese medicine composition is safe and stable, and is suitable for long term eating.

The invention discloses cake sandwiched coarse cereal bread and a preparation method thereof. The cake sandwiched coarse cereal bread is characterized by being composed of, by mass, 1-5 parts of dough, 1-2 parts of cakes, 1-2 parts of coarse cereal particles and 1-2 parts of salad dressing. Based on a traditional Chinese medicine health-preserving theory and a human body dietary structure, a breadoften eaten by people is selected as a carrier, coarse cereals or coarse cereal powder is added into a bread body, meanwhile, a cake with a fine and smooth taste is used as a sandwich in the bread, the defect that the coarse cereals are rough in taste is overcome greatly, and therefore the coarse cereal bread which is nutritional, healthy and fine and smooth in taste is prepared.

The invention discloses a method for preparing a nut soybean sauce, belonging to the technical field of food processing. The method comprises the following steps: I. preparing spice leach liquor, namely boiling anises, gingers and crude salt with water to prepare the spice leach liquor; and II. preparing sauce, namely mixing rice beans, black soyabeans, corns, aspergillus oryzae, flour, sunflower seed kernels, pumpkin seed kernels, apricot kernels, walnut kernels and the spice leach liquor, and fermenting to prepare the paste. The nut soybean sauce disclosed by the invention not only is abundant in natural nutrition, but also has heavy fragrance and crispy taste.

The invention discloses a Chinese medicinal composition for treating a myocardial ischemia heart disease and a preparation method thereof, and relates to the Chinese medicinal composition and the preparation method thereof. The Chinese medicinal composition for treating the myocardial ischemia heart disease is prepared from hypericum attenuatum and root of red-rooted salvia. The method 1 comprises the following steps of: taking the hypericum attenuatum and the root of red-rooted salvia; preparing hypericum attenuatum extract, drying under reduced pressure and then crushing into fine powder A; decocting the root of red-rooted salvia with water and performing reflux extraction to prepare the extract, drying under reduced pressure and then crushing into fine powder B; and mixing the fine powder A with the fine powder B. The method 2 comprises the following steps of: taking the hypericum attenuatum and the root of red-rooted salvia; preparing hypericum attenuatum extract, drying under reduced pressure and then crushing into fine powder A; performing reflux extraction on the root of red-rooted salvia to prepare the extract, drying under reduced pressure and then crushing into fine powder B; and mixing the fine powder A with the fine powder B. In the Chinese medicinal composition, compound compatibility of the hypericum attenuatum and the root of red-rooted salvia is adopted, the hypericum attenuatum and the root of red-rooted salvia can be cooperatively used for relieving symptoms of the myocardial ischemia heart disease, and the composition has an obvious effect, is safe and does not have a toxic or side effect; and the preparation method is simple, easy to operate, low in cost and is suitable for industrial production.

The invention relates to the technical field of food processing, in particular to a beverage containing rose essence and rose fragrance. The beverage comprises the following components in percentagesby weight: 57-60% of collagen, 35-40% of fruit powder, 0.5-1.5% of mangosteen powder, 0.2-0.5% of pomegranate powder, 0.5-1.5% of rose powder and 0.05-0.15% of mogroside. The prepared beverage containing the rose essence and the rose fragrance is low in sugar content, after a user drinks the beverage for a week, the skin whitening effect is improved, the effect of removing freckles on faces is obvious, and the skin color is fine, smooth, ruddy and glossy; the rose powder has effects of regulating QI and harmonizing blood, soothing the liver and resolving depression, reducing blood lipid and reducing weight, moistening skin and nourishing faces and the like, particularly has magical efficacy on woman dysmenorrhea and irregular menstruation, also has the efficacy of whitening the skin, preserving moisture, nourishing faces, regulating menstruation and the like, can have the effects of replenishing blood and nourishing QI, and nourishing faces, and has peculiar efficacy of clearing heat and eliminating fire, and maintaining beauty and keeping young.

The invention discloses application of zinc finger protein 307 (ZNF307) in protecting heart function, resisting cardiac fibrosis and / or preventing and relieving and / or treating myocardial hypertrophy and belongs to the field of gene application. The circumstance that expression of ZNF307 in a model occurring myocardial hypertrophy is remarkably lowered when compared with that of a normal group is determined; inhibition of ZNF307 expression remarkably promotes myocardial hypertrophy and fibrosis and deteriorates the heart function while promotion of overexpression of the ZNF307 remarkably inhibits myocardial hypertrophy and fibrosis and protects the heart function. The ZNF307 can serve as a drug target to be used for screening drug for protecting heart function, resisting cardiac fibrosis and / or preventing and relieving and / or treating myocardial hypertrophy; the ZNF307 can serve as a target gene in gene treatment to be used for designing and preparing drug and / or biological preparations for protecting heart function, resisting cardiac fibrosis and / or preventing and relieving and / or treating myocardial hypertrophy, and a novel effective approach is provided for treatment of myocardial hypertrophy.

The invention discloses an interferon regulatory factor 6(IRF6) and application of an inhibitor of the factor in treatment of myocardial hypertrophy and belongs to the fields of gene function and application. The mutual relation between IRF6 gene expression and the myocardial hypertrophy is determined, wherein the myocardial hypertrophy and fibrosis are remarkably inhibited and cardiac functions are improved by inhibiting the IRF6 expression, and the myocardial hypertrophy and fibrosis are remarkably promoted and the cardiac functions deteriorate by promoting the IRF6 expression. Therefore, the IRF6 can serve as a drug target for screening drugs for protecting the cardiac functions, preventing, relieving and / or treating the myocardial hypertrophy or resisting myocardial fibrosis, the inhibitor of the IRF6 can be used for preparing the drugs for protecting the cardiac functions, preventing, relieving and / or treating the myocardial hypertrophy or resisting myocardial fibrosis.

The invention discloses a function and an application of angiotensin invertaste (ACE3) in treating cardiac hypertrophy, and belongs to the field of function and application of genes. An interrelation between the expression of ACE3 and cardiac hypertrophy is determined, a research result shows that in a model having the cardiac hypertrophy, the expression of the ACE3 is remarkably decreased compared with that of a normal group; the cardiac hypertrophy, fiberization and heart function deteriorate are remarkably promoted by inhibiting the expression of ACE3, the cardiac hypertrophy and fiberization are remarkably inhibited by promoting the over-expression of the ACE3, and the heart function is protected. Therefore, ACE3 can be used as a target gene to screen a drug for protecting the heart function, resisting the fiberization of the heart and / or preventing, alleviating and / or treating cardiac hypertrophy, to prepare a drug for protecting the heart function, resisting the cardiac hypertrophy and / or preventing, alleviating and / or treating cardiac hypertrophy, and an effective new way is provided for treating the cardiac hypertrophy.

The invention discloses functions and application of ribosome GTP enzyme 1 (MTG1) relevant to mitochondria to treatment of myocardial hypertrophy and belongs to the field of functions and application of genes. The mutual relation between expression of MTG1 and myocardial hypertrophy is determined, and the research result shows that in a model where myocardial hypertrophy happens, expression of MTG1 is remarkably reduced compared with a normal group; when expression of MTG1 is inhibited, myocardial hypertrophy and fibrosis are remarkably promoted, and the heart function is deteriorated; when over-expression of MTG1 is promoted, myocardial hypertrophy and fibrosis are remarkably inhibited, and the heart function is protected. Thus, MTG1 can serve as target genes, are used for screening drugs for protecting the heart function, resisting cardiac fibrosis and / or preventing and relieving and / or treating myocardial hypertrophy and are used for preparing drugs for protecting the heart function, resisting cardiac fibrosis and / or preventing and relieving and / or treating myocardial hypertrophy, and a new effective path is provided for treating myocardial hypertrophy.

The invention discloses application of zinc finger protein 307 (ZNF307) in protecting heart function, resisting cardiac fibrosis and / or preventing and relieving and / or treating myocardial hypertrophy and belongs to the field of gene application. The circumstance that expression of ZNF307 in a model occurring myocardial hypertrophy is remarkably lowered when compared with that of a normal group is determined; inhibition of ZNF307 expression remarkably promotes myocardial hypertrophy and fibrosis and deteriorates the heart function while promotion of overexpression of the ZNF307 remarkably inhibits myocardial hypertrophy and fibrosis and protects the heart function. The ZNF307 can serve as a drug target to be used for screening drug for protecting heart function, resisting cardiac fibrosis and / or preventing and relieving and / or treating myocardial hypertrophy; the ZNF307 can serve as a target gene in gene treatment to be used for designing and preparing drug and / or biological preparations for protecting heart function, resisting cardiac fibrosis and / or preventing and relieving and / or treating myocardial hypertrophy, and a novel effective approach is provided for treatment of myocardial hypertrophy.

The invention discloses an application of an interferon regulatory factor 5(IRF5) and an inhibitor thereof in treating cardiac hypertrophy, and belongs to the filed of function and application of genes. The application of the interferon regulatory factor 5(IRF5) and the inhibitor thereof in treating cardiac hypertrophy determines the relationships between the expression of IRF5 genes and cardiac hypertrophy disease. The relationships are inhibiting the expression of the IRF5 genes, accordingly remarkably inhibiting cardiac hypertrophy and fibrosis, and improving cardiac function; promoting the expression of the IRF5 genes, accordingly remarkably promoting cardiac hypertrophy and fibrosis, and deteriorating cardiac function. Thereby, IRF5 can be adopted as a drug target used for screening drugs which protect cardiac function, prevent, relieve and / or treat cardiac hypertrophy and resist myocardial fibrosis. The inhibitor of IRF5 can be used for preparing drugs which protect cardiac function, prevent, relieve and / or treat cardiac hypertrophy and resist myocardial fibrosis.

The invention discloses application of a TRAF-associated NF-[Kappa]B activator (TANK) and inhibitors thereof in treatment of cardiac hypertrophy and belongs to the field of functions and application of genes. According to the application, the interrelationship between the expression of a TANK gene and the cardiac hypertrophy is determined; through inhibiting the expression of the TANK, the hypertrophy and fibrosis of cardiac muscles are inhibited remarkably, and cardiac functions are improved; and through promoting the expression of the TANK, the hypertrophy and fibrosis of the cardiac muscles are promoted remarkably, and the cardiac functions are deteriorated. Therefore, the TANK can be used for screening drugs for protecting the cardiac functions, preventing, relieving and / or treating the cardiac hypertrophy and resisting cardiac fibrosis as a drug target, and the inhibitors of the TANK can be used for preparing drugs for protecting the cardiac functions, preventing, relieving and / or treating the cardiac hypertrophy and resisting the cardiac fibrosis.

The invention discloses application of zinc finger protein 394 in protecting cardiac function, preventing cardiac fibrosis and / or preventing, relieving and / treating myocardial hypertrophy, and belongs to the field of gene applications. Determined are that in a model with myocardial hypertrophy, expression of the ZNF 394 is significantly reduced when compared to a normal group, that inhibition on ZNF 394 expression significantly promotes myocardial hypertrophy and fibrosis and deteriorates cardiac function, and that promotion on ZNF 394 over-expression significantly inhibits myocardial hypertrophy and fibrosis and protects cardiac function. The ZNF 394 may serve as a pharmaceutical target for screening pharmaceuticals used for protecting cardiac function, preventing cardiac fibrosis and / or preventing, relieving and / treating myocardial hypertrophy; the ZNF 394 may serve as a target gene in gene therapy and serve for the design and preparation of the pharmaceuticals / or biological regents used for protecting cardiac function, preventing cardiac fibrosis and / or preventing, relieving and / treating myocardial hypertrophy, and an effective novel way to treat myocardial hypertrophy is provided.

The invention discloses an application of ZNF418 (zinc finger protein 418) to protection of cardiac functions, resistance to cardiac fibrosis and / or prevention, relief and / or treatment of myocardial hypertrophy, and belongs to the application field of genes. In a myocardial hypertrophy model, the expression of the ZNF418 is ensured to be significantly lower than that of a normal group; myocardial hypertrophy and fibrosis are significantly promoted and cardiac functions are deteriorated by inhibiting expression of the ZNF418, and the myocardial hypertrophy and fibrosis are significantly inhibited and the cardiac functions are protected by promoting overexpression of the ZNF418. The ZNF418 can be used as a drug target and used for screening of drugs for protecting the cardiac functions, resisting the cardiac fibrosis and / or preventing, relieving and / or treating the myocardial hypertrophy; the ZNF418 can be used as a target gene for gene therapy and used for designing and preparing drugs and / or biological reagents for protecting the cardiac functions, resisting the myocardial hypertrophy and / or preventing, relieving and / or treating the myocardial hypertrophy, and a new and effective way is provided for treatment of the myocardial hypertrophy.